A. Barrière

Scoring People With Spinal Muscular Atrophy on the Motor Function Measure Using the Microsoft Kinect

L. Servais, C. Vuillerot, P. Rippert, 2022, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

G. Comi, S. Corti, E. Mazzone, 2022, The Lancet Neurology.

Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers’ perspective: a two-part study

C. Vuillerot, R. Arbuckle, T. Duong, 2021, BMC Neurology.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

Psychometric Characteristics of the Motor Function Measure in Neuromuscular Diseases: A Systematic Review1.

C. Pons, C. Vuillerot, P. Rippert, 2023, Journal of neuromuscular diseases.

A Patient-Centered Evaluation of Meaningful Change on the 32-Item Motor Function Measure in Spinal Muscular Atrophy Using Qualitative and Quantitative Data

C. Vuillerot, K. Gorni, T. Duong, 2022, Frontiers in Neurology.

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

R. Finkel, M. Pane, A. Mayhew, 2023, Neurology and Therapy.